Focused On-demand Library for Sodium-dependent phosphate transport protein 2B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O95436

UPID:

NPT2B_HUMAN

Alternative names:

Na(+)-dependent phosphate cotransporter 2B; NaPi3b; Sodium/phosphate cotransporter 2B; Solute carrier family 34 member 2

Alternative UPACC:

O95436; A5PL17; Q8N2K2; Q8WYA9; Q9P0V7

Background:

Sodium-dependent phosphate transport protein 2B, also known as Na(+)-dependent phosphate cotransporter 2B, NaPi3b, and Solute carrier family 34 member 2, plays a crucial role in phosphate homeostasis by actively transporting phosphate into cells via Na(+) cotransport. This protein's function is vital for maintaining the balance of phosphate in the body, which is essential for various biological processes including bone formation and energy metabolism.

Therapeutic significance:

The protein is directly linked to Pulmonary alveolar microlithiasis, a rare disease characterized by calcium phosphate microliths depositing in the lungs, leading to progressive deterioration of lung functions. Understanding the role of Sodium-dependent phosphate transport protein 2B in this condition could pave the way for developing targeted therapies, potentially offering hope for patients suffering from this debilitating disease.